Companion diagnostic testing for targeted cancer therapies: an overview.
作者： Yao-Shan Fan
关键词: KRAS 、 Protein kinase B 、 Melanoma 、 Protein kinase A 、 Bioinformatics 、 Companion diagnostic 、 Cancer 、 Biology 、 Biological pathway 、 ROS1 、 Cancer research
摘要: Genes and their products involved in the biological pathways of human cancers have been studied as either targets new therapies, or predictive markers for sensitivity resistance to therapies. Companion diagnostic testing on targeted cancer therapies has become a vital component personalized treatment. This article provides an overview biomarkers, including EGFR, KRAS, BRAF, ALK, ROS1, HER2, KIT treatment lung, gastrointestinal, colorectal, breast well malignant melanoma. The current approach appears focus single biomarkers. However, comprehensive that includes multimarkers mitogen-activated protein kinase, phosphoinositide 3-kinase/protein kinase B, mammalian target rapamycin may more desirable some cancers, because therapy can be caused by mutations different genes availability ne...
pubmed.cn
elsevier.com参考文章(90)
Jennifer S Lin, Elizabeth M Webber, Caitlyn A Senger, Rebecca S Holmes, Evelyn P Whitlock, Systematic review of pharmacogenetic testing for predicting clinical benefit to anti-EGFR therapy in metastatic colorectal cancer American Journal of Cancer Research. ,vol. 1, pp. 650- 662 ,(2011)
Christine L.H. Snozek, Dennis J. O'Kane, Alicia Algeciras-Schimnich, Pharmacogenetics of Solid Tumors: Directed Therapy in Breast, Lung, and Colorectal Cancer The Journal of Molecular Diagnostics. ,vol. 11, pp. 381- 389 ,(2009) , 10.2353/JMOLDX.2009.090003
Lisa Sarran, Peter Besmer, Ronald P DeMatteo, Sylvia J Tschernyavsky, Marc Ladanyi, Robert Maki, Mark Robson, Elyn Riedel, James M Woodruff, Murray F Brennan, Cristina R Antonescu, Gunhild Sommer, Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clinical Cancer Research. ,vol. 9, pp. 3329- 3337 ,(2003)
Myra F. Barginear, Veena John, Daniel R. Budman, Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer. Molecular Medicine. ,vol. 18, pp. 1473- 1479 ,(2012) , 10.2119/MOLMED.2012.00302
Kaori Fujimoto-Ouchi, Fumiko Sekiguchi, Hideyuki Yasuno, Yoichiro Moriya, Kazushige Mori, Yutaka Tanaka, Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models. Cancer Chemotherapy and Pharmacology. ,vol. 59, pp. 795- 805 ,(2007) , 10.1007/S00280-006-0337-Z
Daniel B. Costa, Susan T. Schumer, Daniel G. Tenen, Susumu Kobayashi, Differential Responses to Erlotinib in Epidermal Growth Factor Receptor (EGFR)-Mutated Lung Cancers With Acquired Resistance to Gefitinib Carrying the L747S or T790M Secondary Mutations Journal of Clinical Oncology. ,vol. 26, pp. 1182- 1184 ,(2008) , 10.1200/JCO.2007.14.9039
Wendy De Roock, Derek J. Jonker, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Dongsheng Tu, Salvatore Siena, Simona Lamba, Sabrina Arena, Milo Frattini, Hubert Piessevaux, Eric Van Cutsem, Chris J. O’Callaghan, Shirin Khambata-Ford, John R. Zalcberg, John Simes, Christos S. Karapetis, Alberto Bardelli, Sabine Tejpar, Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab JAMA. ,vol. 304, pp. 1812- 1820 ,(2010) , 10.1001/JAMA.2010.1535
Takayuki Kosaka, Yasushi Yatabe, Hideki Endoh, Kimihide Yoshida, Toyoaki Hida, Masahiro Tsuboi, Hirohito Tada, Hiroyuki Kuwano, Tetsuya Mitsudomi, Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib Clinical Cancer Research. ,vol. 12, pp. 5764- 5769 ,(2006) , 10.1158/1078-0432.CCR-06-0714
Antoni Ribas, Keith T. Flaherty, BRAF targeted therapy changes the treatment paradigm in melanoma Nature Reviews Clinical Oncology. ,vol. 8, pp. 426- 433 ,(2011) , 10.1038/NRCLINONC.2011.69
Natalie Galanina, Veerle Bossuyt, Lyndsay N. Harris, Molecular Predictors of Response to Therapy for Breast Cancer The Cancer Journal. ,vol. 17, pp. 96- 103 ,(2011) , 10.1097/PPO.0B013E318212DEE3